Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-7828 SAD and Food Effect Study in Healthy Adults
NCT07856706Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial of ABBV-7828 (4 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events at 38 days, Maximum Observed Serum Concentration at 10 days and 4 more. Started Oct 2026; status: recruiting.
02
Drugs
ABBV-7828
Beyond the preview
Go deeper on NCT07856706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07856706.